SKIN HOMOGRAFTS IN PATIENTS WITH CANCER OF THE CERVIX.
Skin homografts were applied to patients with cervical cancer. In 9% (10 of 110) of untreated patients, grafts survived for more than two weeks. The frequency of prolonged graft survival was increased by pelvic surgery or radiotherapy. It was highest, 62% (34 of 55), in those with recurrent cancer. Recurrence and death in patients studied prior to treatment and followed up six months to two and a half years was three times more frequent in those with grafts tolerated over two weeks than in those rejecting them in a shorter period, i.e. five of 10 and 10 of 74, respectively.
D064591:Allografts; D005260:Female; D006801:Humans; D007044:Hysterectomy; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000453:epidemiology* / Q000276:immunology* / Q000532:radiotherapy*; D010336:Pathology; D011379:Prognosis; D011827:Radiation; D011830:Radiation Effects / Q000276:immunology*; D012106:Research; D016038:Skin Transplantation; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D002583:Uterine Cervical Neoplasms
CERVIX NEOPLASMS; HYSTERECTOMY; NEOPLASM IMMUNOLOGY; NEOPLASM RADIOTHERAPY; NEOPLASM STATISTICS; PATHOLOGY; PROGNOSIS; RADIATION IMMUNOLOGY; SKIN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS